December 3, 2021 -- SQZ Biotechnologies, a clinical-stage cell therapy biotechnology company that develops treatments for patients with cancer, infectious diseases, and autoimmune conditions, announced that its SQZ China Initiative has been accepted by the Roche Accelerator in China.
Roche's accelerator is the company's first in-house global accelerator and further establishes its long-term commitment to Shanghai and China. Embedded in the Roche R&D organization, the accelerator empowers entrepreneurs to bridge the gap between concept and proof of concept. Roche provides seed funding, support through intensive coaching and guidance, physical infrastructure and operations, and flexibility tailored to each entrepreneur.
China's healthcare ecosystem is of growing global importance and offers significant opportunities for patient impact, SQZ Biotech said. Collaborating with the Roche Accelerator will support SQZ Biotech's early strategic planning, market exploration, and potential China-based activities for the SQZ China Initiative.
"We are excited to be one of the first members of the Roche Accelerator and to begin working with its talented experts to support strategic planning for this important global healthcare center," Armon Sharei, PhD, chief executive officer and founder of SQZ Biotechnologies, said.
Roche and SQZ Biotech have been strategic partners since 2015. Roche has an ongoing collaboration on the SQZ antigen-presenting cell oncology platform globally.
Copyright © 2021 scienceboard.net